Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • Trump executive order lifts psychedelics biotechs
  • Policy / Pricing

Trump executive order lifts psychedelics biotechs

BioPharma Dive

Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more investable space.

Policy / PricingNeuroscienceRead full story

pharminent April 21, 2026 (Last updated: April 21, 2026)

BioPharma Dive

Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more investable space.

Policy / PricingNeuroscienceRead full story

Post navigation

Previous: RFK Jr. defends HHS tenure, 12% proposed budget cut
Next: Asahi Kasei acquires German company Aicuris

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.